SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Vir Biotechnology Inc

Vir Biotechnology is actively discussed after announcing a major strategic collaboration with Astellas for its prostate cancer treatment, VIR-5500, featuring substantial upfront payments and positive Phase 1 data, leading to bullish community speculation about a short squeeze and re-evaluation of its immuno-oncology pipeline.

The Home Depot, Inc. engages in the sale of building materials and home improvement products. Its products include building materials, home improvement products, lawn and garden products and decor products. The firm operates through the following geographical segments: U.S., Canada and Mexico. It offers home improvement installation services, and tool and rental equipment. The company was founded by Bernard Marcus, Arthur M. Blank, Kenneth Gerald Langone and Pat Farrah on June 29, 1978 and is headquartered at Atlanta, GA.

Home Depot, Inc.

Home Depot is experiencing active discussion after its latest earnings beat initial profit estimates but offered cautious fiscal year guidance, sparking a mixed community reaction on whether lingering housing market headwinds and consumer spending hesitation will support a rebound or continued pressure.

CrowdStrike Holdings, Inc. provides cybersecurity products and services to stop breaches. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. CrowdStrike serves customers worldwide. The company was founded by George P. Kurtz, Gregg Marston, and Dmitri Alperovitch on November 7, 2011 and is headquartered in Austin, TX.

Crowdstrike Holdings Inc - Ordinary Shares - Class A

Crowdstrike Holdings Inc

CrowdStrike is trending amidst a sector-wide sell-off sparked by fears that Anthropic's new Claude Code Security tool signals AI's disruptive potential in cybersecurity, though the community remains sharply divided between those who believe it's an overblown reaction and others concerned about long-term business model changes.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU CRYPTO is trending as its highly active community demonstrates strong conviction, consistently building a permissionless brand with numerous real-world products and initiatives. The community's unwavering focus on development and "buying the dip" in a fluctuating market generates significant discussion and belief in its long-term potential.

Atlassian Corp. is a holding company, which engages in providing team collaboration and productivity software. Its products include Jira Software, Confluence, Jira Service Management, and Loom. The company was founded by Michael Cannon-Brookes and Scott Farquhar in October 2002 and is headquartered in San Francisco, CA.

Atlassian Corporation - Ordinary Shares - Class A

Atlassian Corporation Plc

Atlassian (TEAM) is trending as widespread market fears of AI disruption drive a "SaaSpocalypse" across the software sector, overshadowing the company's solid earnings. While many investors are panicking over potential obsolescence from AI tools, others view the sharp sell-off as an extreme undervaluation for Atlassian's deeply embedded and sticky enterprise solutions.

Federal National Mortgage Association is a government-sponsored company, which engages in the provision of liquidity for purchases of homes and financing of multifamily rental housing and refinancing existing mortgages. It operates through the Single-Family and Multifamily segments. The Single-Family segment offers liquidity to the mortgage market and increases the availability and affordability of housing for single families. The Multifamily segment includes guaranty fees on mortgages and on multifamily mortgage loans. The company was founded in 1938 and is headquartered in Washington, DC.

Federal National Mortgage Association

Fannie Mae (FNMA) is trending as positive housing market forecasts and decreasing mortgage rates, alongside recent strong earnings reports from the GSEs, fuel investor anticipation for its release from conservatorship. The community is keenly discussing comments from FHFA leadership indicating readiness for an IPO with the decision resting with the President, leading to widespread speculation of an imminent uplisting to the NYSE.

Armstrong World Industries, Inc. engages in the design, manufacture, and trade of commercial and residential ceiling, wall, and suspension system solutions. It operates through the following segments: Mineral Fiber, Architectural Specialties, and Unallocated Corporate. The Mineral Fiber segment involves the production of suspended and soft fiber ceiling systems. The Architectural Specialties segment focuses on the production, design, and sourcing of ceilings, walls, and facades primarily for use in commercial settings. The Unallocated Corporate segment includes the assets, liabilities, income, and expenses that have not been allocated to other business segments. The company was founded by Thomas M. Armstrong in 1860 and is headquartered in Lancaster, PA.

Armstrong World Industries Inc.

Armstrong World Industries is trending after reporting strong Q4 2025 earnings and issuing robust 2026 guidance, with the community highlighting its strategic acquisitions and product innovations in architectural solutions. This performance showcases the company's resilience and growth drivers despite a dynamic building materials market.

DigitalOcean Holdings, Inc. engages in the provision of providing cloud infrastructure. It operates through the following geographical segments: United States, Netherlands, Germany, Canada, Singapore, and Other. The company was founded in 2012 and is headquartered in Broomfield, CO.

DigitalOcean Holdings Inc

DigitalOcean is experiencing a significant uplift following a strong earnings report and optimistic guidance, driving community chatter around its pivotal role in the burgeoning agentic AI infrastructure and its strategic partnership with AMD.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is experiencing its steepest market decline in over two decades after Anthropic claimed its Claude Code can automate COBOL modernization, raising fears of AI disruption to IBM's legacy services. The community is intensely debating whether this is an overreaction, with many highlighting IBM's existing AI partnerships, Watsonx platform, and leadership in hybrid cloud and quantum computing as strong counterpoints to the perceived threat.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is soaring after announcing 700% revenue growth for its ANKTIVA platform, driven by recent global approvals and an aggressive 3-year expansion plan for multiple cancer and immune system treatments. The community anticipates a significant short squeeze amid elevated short interest and discussions of potential high-profile recognition for its groundbreaking oncology advancements.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Achieve Life Sciences (NASDAQ:ACHV) Stock Crosses Above 200 Day Moving Average - What's Next?

Achieve Life Sciences (NASDAQ:ACHV) Shares Pass Above Two Hundred Day Moving Average - Here's What Happened...

Achieve Life Sciences, Inc. (NASDAQ:ACHV) Given Consensus Rating of "Moderate Buy" by Brokerages

Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV - Get Free Report) have earned an average recommendation of "Moderate Buy" from the five analysts that are presently covering the company...

Achieve Life Sciences (NASDAQ:ACHV) Stock Price Crosses Above 200-Day Moving Average - Here's Why

Achieve Life Sciences (NASDAQ:ACHV) Stock Crosses Above Two Hundred Day Moving Average - What's Next...

What is HC Wainwright's Forecast for ACHV FY2030 Earnings?

Achieve Life Sciences, Inc. (NASDAQ:ACHV - Free Report) - HC Wainwright issued their FY2030 EPS estimates for shares of Achieve Life Sciences in a note issued to investors on Monday, January 26th. HC...

Achieve Life Sciences (NASDAQ:ACHV) Stock Passes Above Two Hundred Day Moving Average - Here's What Happened

Achieve Life Sciences (NASDAQ:ACHV) Shares Pass Above Two Hundred Day Moving Average - Time to Sell...

Achieve Life Sciences Promotes Mark Rubinstein As Chief Medical Officer

(RTTNews) - Achieve Life Sciences, Inc. (ACHV), a late-stage specialty pharmaceutical company, said Monday it has confirmed the promotion of Mark Rubinstein from Interim Chief Medical Officer to...

Achieve Life Sciences (NASDAQ:ACHV) Share Price Crosses Above 200-Day Moving Average - Here's Why

Achieve Life Sciences (NASDAQ:ACHV) Stock Price Crosses Above Two Hundred Day Moving Average - Should You Sell...

<p>Hunterbrook Capital on Tuesday revealed it is long on Achieve Life Sciences (ACHV) stock as the company nears a green light from the U.S. Food and Drug Administration for Cytisinicline as a treatment for smoking addiction.</p><p>The FDA is expected to rule on Achieve Life Sciences’ application seeking approval for the drug by June 20, 2026. If approved, the company plans to sell it in the U.S. by the end of the year.</p><p>Hunterbrook Media <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://hntrbrk.com/achieve/">said</a> that Cytisinicline is already used in Europe and added that smoking cessation clinicians, scientists, and health program directors that it interviewed recommended approval in the U.S.</p><p>The report also noted that Cytisinicline has proven safer and more effective than its predecessors including Pfizer’s Chantix and GlaxoSmithKline’s Zyban. Chantix, despite side effects, earned over $1 billion in peak annual sales and it, like GSK’s Zyban, also required longer treatment than Cytisinicline, the firm said.</p><p>Furthermore, despite smoking being on the decline, it is still rampant, the firm noted.</p><p>There are about 29 million American cigarette smokers and about 28 million e-cigarette users, including many middle and high schoolers, the firm said. While about a half of this population try to quit, only a small portion succeeds.</p><h2 class="st-heading-2">FDA Priority Review Voucher</h2><p>The FDA awarded Achieve a Commissioner's National Priority Voucher (CNPV) aimed at expediting review for Cytisinicline in October. “It's been nearly two decades since a new treatment option for smoking cessation was approved, and there are currently no treatment options for vaping cessation,” Achieve CEO Rick Stewart said then.</p><h2 class="st-heading-2">Hunterbrook Flags Potential Headwinds</h2><p>“As with all applications, the FDA could still require additional data or studies if any safety concerns arise. Achieve also needs to maintain long-term access to cytisinicline supply. &nbsp;The company is in a legal dispute with its original supplier, Sopharma, though Achieve named other suppliers in its FDA application,” Hunterbrook said.</p><p>The firm also flagged funding concerns, highlighting that while Achieve is funded through the second quarter of 2026, it will need to raise more capital to commercialize the drug after receiving approval.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>ACHV stock traded 7% higher at the time of writing. On Stocktwits, retail sentiment around ACHV jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to 'normal' levels.</p><p><a href="https://stocktwits.com/symbol/ACHV">ACHV stock</a> has gained 34% this year and by about 31% over the past 12 months.&nbsp;</p><p>Also See: <a href="https://stocktwits.com/news-articles/markets/equity/walmart-app-website-down-for-users-amid-new-year-shopping-rush/cL7I4vlREyI">Walmart App And Website Down For Users Amid New Year Shopping Rush</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

In this photo illustration, the Achieve Life Sciences logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Achieve Life Sciences’ Smoking Treatment Likely To Be Approved By FDA, Says Hunterbrook

The FDA is expected to rule on Achieve Life Sciences’ application seeking approval for the drug by June 20, 2026.

Equity

Achieve Life Sciences (NASDAQ:ACHV) Shares Cross Above Two Hundred Day Moving Average - Here's Why

Achieve Life Sciences (NASDAQ:ACHV) Stock Passes Above Two Hundred Day Moving Average - What's Next...

Achieve Life Sciences, Inc. (NASDAQ:ACHV) Given Average Rating of "Moderate Buy" by Analysts

Achieve Life Sciences, Inc. (NASDAQ:ACHV - Get Free Report) has earned an average recommendation of "Moderate Buy" from the five brokerages that are covering the stock, MarketBeat Ratings reports...

Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products includes cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.

Current Price	$4.22
Prev Close	$4.27
Open	$4.27
Dividend Yield	0.00%
50-Day Moving Average	$4.71
Beta	1.18
Avg. Volume	840,367.70
PE Ratio	-3.10

52-Week High	$6.03
52-Week Low	$1.84
Market Capitalization	$227.31M
EPS (Annual)	-$1.24
Price to Book	6.71
Revenue Per Employee	$0.00

ACHV
Achieve Life Sciences Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ACHV News

ACHVAchieve Life Sciences Inc.